Page 28 - Read Online

Chen et al. Hepatoma Res 2018;4:72 I http://dx.doi.org/10.20517/2394-5079.2018.103 Page 15 of 16

38. Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin- bound alpha-
fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009;137:110-8.
39. Nakamura S, Nouso K, Sakaguchi K, Ito YM, Ohashi Y, et al. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis
of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol 2006;101:2038-43.
40. Ji J, Wang H, Li Y, Zheng L, Yin Y, et al. Diagnostic evaluation of des-gamma-carboxy prothrombin versus α-fetoprotein for hepatitis B
virus-related hepatocellular carcinoma in china: a large-scale, multicentre study. PLoS One 2016;11:1-17.
41. Gentile I, Buonomo AR, Scotto R, Zappulo E, Carriero C, et al. Diagnostic accuracy of PIVKA-II, alpha-fetoprotein and a combination of
both in diagnosis of hepatocellular carcinoma in patients affected by chronic HCV infection. In Vivo 2017;31:695-700.
42. Liao W, Mao Y, Ge P, Yang H, Xu H, et al. Value of quantitative and qualitative analyses of circulating cell-free DNA as diagnostic tools for
hepatocellular carcinoma. Medicine (Baltimore) 2015;94:e722.
43. Zhou J, Huang A, Yang XR. Liquid biopsy and its potential for management of hepatocellular carcinoma. J Gastrointest Cancer
2016;47:157-67.
44. Li LM, Hu Z Bin, Zhou ZX, Chen X, Liu FY, et al. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis
of HBV-positive hepatocarcinoma. Cancer Res 2010;70:9798-807.
45. Hung CH, Hu TH, Lu SN, Kuo FY, Chen CH, et al. Circulating microRNAs as biomarkers for diagnosis of early hepatocellular carcinoma
associated with hepatitis B virus. Int J Cancer 2016;138:714-20.
46. Tat Trung N, Duong DC, Tong HV, Hien TTT, Hoan PQ, et al. Optimisation of quantitative miRNA panels to consolidate the diagnostic
surveillance of HBV-related hepatocellular carcinoma. PLoS One 2018;13:1-17.
47. Motawi TK, Shaker OG, El-Maraghy SA, Senousy MA. Serum MicroRNAs as potential biomarkers for early diagnosis of hepatitis C virus-
related hepatocellular carcinoma in egyptian patients. PLoS One 2015;10:1-23.
48. Jepsen P, Ott P, Andersen PK, Sorensen HT, Vilstrup H. Risk for hepatocellular carcinoma in patients with alcoholic cirrhosis: a Danish
nationwide cohort study. Ann Intern Med 2012;156:841-7, W295.
49. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, et al. The incidence and risk factors of hepatocellular carcinoma in patients
with nonalcoholic steatohepatitis. Hepatology 2010;51:1972-8.
50. White D, Kanwal F, El-Serag H. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic
review. Clin Gastroenterol Hepatol 2012;10:1342-59.
51. Mittal S, Sada YH, El-Serag HB, Kanwal F, Duan Z, et al. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular
carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol 2015;13:594-601.e1.
52. Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol 2013;47 Suppl:S2-6.
53. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective
follow-up study of 384 patients. Gastroenterology 1997;112:463-72.
54. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver
disease. N Engl J Med 1993;328:1797-801.
55. Jakobsen JC, Nielsen EE, Feinberg J, Katakam KK, Fobian K, et al. Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst
Rev 2017;9:CD012143.
56. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related
cirrhosis treated with direct-acting antivirals. J Hepatol 2016;65:727-33.
57. Singh S, Nautiyal A, Loke YK. Oral direct-acting antivirals and the incidence or recurrence of hepatocellular carcinoma: a systematic
review and meta-analysis. Frontline Gastroenterol 2018;9:262-70.
58. Singal AG, Pillai A, Tiro J. Early Detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with
cirrhosis: a meta-analysis. PLoS Med 2014;11:e1001624.
59. Kansagara D, Papak J, Pasha AS, O’Neil M, Freeman M, et al. Screening for hepatocellular carcinoma in chronic liver disease: a systematic
review. Ann Intern Med 2014;161:261-9.
60. Yuen MF, Cheng CC, Lauder IJ, Lam SK, Ooi CG, et al. Early detection of hepatocellular carcinoma increases the chance of treatment:
Hong Kong experience. Hepatology 2000;31:330-5.
61. Noda I, Kitamoto M, Nakahara H, Hayashi R, Okimoto T, et al. Regular surveillance by imaging for early detection and better prognosis of
hepatocellular carcinoma in patients infected with hepatitis C virus. J Gastroenterol 2010;45:105-12.
62. van Meer S, de Man RA, Coenraad MJ, Sprengers D, van Nieuwkerk KM, et al. Surveillance for hepatocellular carcinoma is associated
with increased survival: results from a large cohort in the Netherlands. J Hepatol 2015;63:1156-63.
63. Chaiteerakij R, Chattieng P, Choi J, Pinchareon N, Thanapirom K, et al. Surveillance for hepatocellular carcinoma reduces mortality: an
inverse probability of treatment weighted analysis. Ann Hepatol 2017;16:421-9.
64. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the
PRISMA statement. PLoS Med 2009;6:e1000097.
65. Chiang JK, Chih-Wen L, Kao YH. Effect of ultrasonography surveillance in patients with liver cancer: a population-based longitudinal
study. BMJ Open 2017;7:e015936.
66. Mittal S, Kanwal F, Ying J, Chung R, Sada YH, et al. Effectiveness of surveillance for hepatocellular carcinoma in clinical practice: a United
States cohort. J Hepatol 2016;65:1148-54.
67. Cucchetti A, Trevisani F, Pecorelli A, Erroi V, Farinati F, et al. Estimation of lead-time bias and its impact on the outcome of surveillance for
the early diagnosis of hepatocellular carcinoma. J Hepatol 2014;61:333-41.
68. El-Serag HB, Kramer JR, Chen GJ, Duan Z, Richardson PA, et al. Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma
mortality in HCV-infected patients in the USA. Gut 2011;60:992-7.
69. Stroffolini T, Trevisani F, Pinzello G, Brunello F, Tommasini MA, et al. Changing aetiological factors of hepatocellular carcinoma and their
potential impact on the effectiveness of surveillance. Dig Liver Dis 2011;43:875-80.